Jefferies assumed coverage of Liquidia (LQDA) with a Buy rating and a price target of $43, up from $31. The firm expects Yutrepia to beat FY25 estimates and for the company to hit profitability in Q4 of 2025, adding that it views it as “highly unlikely” Yutrepia is pulled off the market due to United Therapeutics’ (UTHR) patent litigation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Strong Initial Performance and Strategic Market Entry of Liquidia Technologies’ Yutrepia Drives Buy Rating
- Liquidia Corporation’s Strong Launch of YUTREPIA
- Liquidia price target raised to $35 from $23 at BofA
- Liquidia price target raised to $31 from $25 at Wells Fargo
- Promising Outlook for Liquidia Technologies: Strong Start for Yutrepia Drives Buy Rating